Nordin K, Fredriksson T, Rylander C
Dermatologica. 1981;162(2):104-11. doi: 10.1159/000250256.
The clinical efficacy and tolerance of a new retinoic acid derivative, Ro 11-1430, in the treatment of acne vulgaris have been compared with those of tretinoin in a double-blind trial with 60 patients during 8 weeks. The efficacy of both drugs was good. Tretinoin showed a tendency to give better effect but this was not statistically significant. However, tolerance of the new derivative was better. 48 of the patients were treated with Ro 11-1430 for another 3 months with good effect and tolerance. In a long-term study, 32 patients with previous irritation of tretinoin have been treated with Ro 11-1430 between 1.5 and 17 months with good tolerance.
在一项为期8周的双盲试验中，对60名患者比较了一种新型维甲酸衍生物Ro 11-1430与维甲酸治疗寻常痤疮的临床疗效和耐受性。两种药物的疗效均良好。维甲酸显示出效果更佳的趋势，但无统计学意义。然而，新衍生物的耐受性更好。48名患者用Ro 11-1430再治疗3个月，效果和耐受性良好。在一项长期研究中，32名曾对维甲酸有过刺激反应的患者用Ro 11-1430治疗了1.5至17个月，耐受性良好。
